VS Venture Associate

We are Alloy Therapeutics —a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, we democratize access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma.

At Alloy, we believe our industry should compete on getting the best drugs to patients as quickly as possible, not exclusive access to the best platforms. As a reflection of our relentless commitment to the scientific community, we reinvest 100% of our revenue in innovation and access to innovation.

Alloy has evolved from a startup into a global biotechnology infrastructure company operating 11 divisions across 5 research sites in 4 countries on 3 continents. Our model - Integrated Independence - combines centralized capabilities with entrepreneurial operating divisions. Successful members thrive in our shared culture of accountability, deliberate trust, and open communication. As a team we aspire to work together to exceed expectations and collectively contribute across the global organization to always maintain our nimble, startup culture.

In 2020, Alloy launched 82VS, which builds and invests in early stage biotechnology startups leveraging the tools and capabilities of the Alloy ecosystem. To date 82VS has founded 15 asset-focused companies developing new medicines across the areas of oncology, immunology, ophthalmology, neurology, and rare diseases. Our current companies are developing antibody, antisense oligonucleotide, and TCR mimic therapeutics, but we are also working actively to build out multimodal therapeutics and expand our delivery capabilities (e.g., antibody shuttles, LNPs, peptides).

In 2020, Alloy launched 82VS, which builds and invests in early stage biotechnology startups leveraging the tools and capabilities of the Alloy ecosystem. To date 82VS has founded 15 asset-focused companies developing new medicines across the areas of oncology, immunology, ophthalmology, neurology, and rare diseases. Our current companies are developing antibody, antisense oligonucleotide, and TCR mimic therapeutics, but we are also working actively to build out multimodal therapeutics and expand our delivery capabilities (e.g., antibody shuttles, LNPs, peptides).

The 82VS core team is based out of our headquarters in Waltham, MA. Our team offers a balance of working in the office and remotely from your home office. We prioritize in person engagement for team collaboration and discussions, which is typically at least three days per week in office.

There are significant opportunities for career advancement and apprenticeship mentorship inside Alloy, through our affiliated venture studio and across our network of over 100 affiliated and partner companies.

MAY THE BEST DRUG WIN.

We are hiring a (Senior) Venture Associate who is passionate about biotech company building, operating, and investing. Venture Associates at 82VS will be exposed to all aspects of new company building, including science, therapeutic discovery and development, strategy, financing, operations, and legal. This is a full-time position targeting a start date of late summer/early fall 2026 in Waltham, MA. For more information on the 82VS team, see our webpage here.

• Two year program after which the expectation is that the associate would move into a portfolio company they have been supporting or started within 82VS
• Venture Studios team member supporting company building and due diligence across 2-3 New Cos
• Lead deep dives into an area of interest for the Venture Studios team, ideally culminating in an investment or company build recommendation
• Support current portfolio companies and pipeline projects with operations, strategy, and technical projects
• Conduct diligence on competitive landscape, unmet clinical need, biological validation, and other key areas to assess…